Multiple Sclerosis Clinical Trial
Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS
Summary
The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.
Full Description
The purpose of this study is to characterize the full pharmacokinetic and pharmacodynamics profiles of RPC1063 in patients with relapsing multiple sclerosis (RMS) following multiple-dose administration of the two different dosing regimens that are being evaluated in the Phase 3 RMS studies.
Eligibility Criteria
Key Inclusion Criteria:
MS, as diagnosed by the revised 2010 McDonald criteria
Exhibits a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS
Expanded disability status scale (EDSS) score between 0 and 6.0
Key Exclusion Criteria:
Primary progressive MS
Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Long Beach California, 90806, United States
San Francisco California, 94158, United States
Raleigh North Carolina, 27607, United States
Akron Ohio, 44320, United States
Knoxville Tennessee, 37922, United States
Round Rock Texas, 78681, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.